These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2006-003900-20 Essai clinique de Phase II évaluant une chimitohérapie systémique associée au Cetuximab en traitement adjuvant chez des patients complètement résèques par chirurgie de leur carcinose péritonéale isolé... 2017-03-01 due-trials
Reported results 2007-004216-31 Réponse au traitement néoadjuvant par l'anti-aromatase anastrozole et l'anti-oestrogène pur fulvestrant : étude de phase II randomisée chez des patientes ménopausées atteintes d'un cancer du sein non ... 2017-03-28 due-trials
Not reported 2008-001506-16 Diffuse large B cell non-hodgkin's lymphoma in the vulnerable/frail elderly. A multicentrix randomized phase II trial with emphasis on geritaric assesment and quality of life. 2017-12-20 due-trials
Ongoing 2008-002730-30 A PHASE II TRIAL TO ASSESS THE EFFICACY OF EFAVIRENZ IN METASTATIC PATIENTS WITH ANDROGEN-INDEPENDENT PROSTATE CANCER not-yet-due
Ongoing 2008-004273-18 A phase II trial to assess the efficacy of efavirenz as second-line monotherapy for the treatment of advanced pancreatic adenocarcinomas. not-yet-due
Reported results Terminated 2008-007094-20 Étude multicentrique de phase III évaluant L’efficacité d’une stratégie d’adaptation de dose de l’imatinib mésylate sur la réponse moléculaire chez des patients présentant une leucémie myéloïde chroni... 2017-03-06 due-trials
Reported results 2009-011049-15 Evaluation de l’efficacité du temsirolimus chez des patients récidivant d’un cancer de la vessie après une première ligne de chimiothérapie. Essai clinique de phase II multicentrique. 2015-08-15 due-trials
Completed, but no date 2010-019817-20 A phase II study of GDC-0449 in patients with advanced chondrosarcomas. bad-data
Reported results 2011-006037-42 Efficacité et tolérance du Pazopanib dans les tumeurs desmoides : essai de phase 2 randomisé 2019-06-11 due-trials
Reported results 2013-000283-28 Efficacy and Safety of PD-0332991 in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Phase 2 study Efficacité et tolérance du PD-0332991 chez les pati... 2018-02-07 due-trials
Exempt, with results 2014-000196-85 A phase Ib study of metronomic Cyclophosphamide and Methotrexate combined with Zoledronic acid and Sirolimus in patients with solid tumor with bone metastasis and advanced pretreated Osteosarcoma. not-yet-due
Exempt 2015-002760-16 Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly trabectedin combined with Metronomic Cyclophosphamide in Patients with Advanced Pretreated Soft-tissue Sarcomas. A Phase I/II study ... not-yet-due
Ongoing 2018-000186-36 Phase III trial investigating the potential benefit of intensified peri-operative Chemotherapy in patients with in high-risk CINSARC patients with resectable soft-tissue SARComas not-yet-due
Other 2018-003835-31 Targeting ATR in soft-tissue sarcomas: a randomized phase II study. TARSARC study Ciblage d’ATR dans les sarcomes des tissus mous : une étude randomisée de phase II. Etude TARSARC not-yet-due
Ongoing 2019-000850-78 Atezolizumab combined with BDB001 and immunogenic radiotherapy in participants with advanced solid tumors. Association de l’atezolizumab, du BDB001 et de la radiothérapie immunogénique chez les pat... not-yet-due
Ongoing 2019-002332-81 CombinatiOn of NivolumAb plus Relatlimab in patients with Advanced or metastatic soft-tissue Sarcoma: a proof-of-concept randomized phase II study Association du nivolumab et du relatlimab chez les... not-yet-due
Ongoing 2020-005562-34 Integrative analysis of the tumor microenvironment and optimization of the immunotherapy duration in non-small cell lung cancer patients. OPTIMUNE-LUNG study Analyse intégrée du microenvironnement ... not-yet-due
Ongoing 2022-001114-19 Lurbinectedin combined with durvalumab (MEDI 4736) in pre-treated patients with extensive stage small-cell lung cancer Lurbinectedine combinée au durvalumab (MEDI 4736) chez les patients prétraités... not-yet-due